Drugs / Virgin Coconut Oil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05441813 | Feb 2023 → Jul 2036 expected | chemotherapy-induced oral mucositis | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT04849637 | Oct 2020 → Apr 2022 | COVID-19 | University of the Philippines | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Virgin Coconut Oil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04849637 ↗ |
| Known as | VCO | “This is a research that will investigate the safety and efficacy of virgin coconut oil (VCO) as an adjunctive therapy for Coronavirus Disease 2019 (COVID-19)” NCT04849637 ↗ |
| Route | Oral | “Oral supplementation of virgin coconut oil to COVID-19 patients” NCT04849637 ↗ |